Compass Therapeutics, Inc. (CMPX) Financial Statements
Compass Therapeutics, Inc. (CMPX) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$73.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$56.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CMPXCompass Therapeutics, Inc.Follow CMPX — free
—
Price chart with a free account
- Market cap
- 137.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 0.9 | 0.0 | — | |
| Research & development | 42.3 | 56.0 | 59.5 | |
| Operating income | -56.6 | -72.8 | -81.1 | |
| Pre-tax income | -49.4 | -66.5 | -73.4 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -49.4 | -66.5 | -73.4 | |
| Diluted shares (mn) | 137.4 | — | — |
USD millions · SEC XBRL
Compass Therapeutics, Inc. — questions
- What is Compass Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Compass Therapeutics, Inc.'s net income?
- -$73.4M over the twelve months to 2026-06-30.
- What is Compass Therapeutics, Inc.'s free cash flow?
- -$56.4M over the twelve months to 2026-06-30.
Every figure on this page comes from Compass Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.